In the BFORE Trial of BOSULIF vs imatinib
47% of patients receiving BOSULIF achieved MMR
at 12 months vs 37% with imatinib (P=0.0200)
1,a
BOSULIF significantly improved CCyR by 12 months vs imatinib
(77% vs 66%, respectively; P=0.0075) 1,a
BFORE: A two-arm, open-label, randomized, multicenter trial conducted to investigate the efficacy and
safety of BOSULIF 400 mg once daily compared with imatinib 400 mg once daily in adult patients with
newly diagnosed chronic phase Ph+ CML (N=487)
The most common adverse reactions reported in patients receiving BOSULIF
(all grades vs imatinib) were diarrhea (70% vs 34%), nausea (35% vs 38%),
thrombocytopenia (35% vs 20%), rash (34% vs 21%), increased ALT (31% vs 6%),
abdominal pain (25% vs 15%), and increased AST (23% vs 6%)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2 :
Bosutinib (BOSULIF) is recommended by the NCCN Guidelines® as a primary treatment
option (category 1) for newly diagnosed patients with CML in need of TKI therapy.
Visit BosulifHCP.com to learn more abou